Page 1129 - Clinical Immunology_ Principles and Practice ( PDFDrive )

ChaPter 80 Monoclonal Gammopathies 1093

In HCDD, a population of clonal plasma cells produces both Lancet Oncol 2014;15(12):e538–48. doi:10.1016/S1470-2045(14)70442-5.
light and heavy monoclonal immunoglobulin chains or only PubMed PMID: 25439696.
short (truncated) heavy chains that are unable to form amyloid 9. Rajkumar SV. Overview of the management of multiple myeloma.
fibrils but are deposited as granules in the tissues. HCDD can UpToDate: Wolters Kluwer; 2016.
be identified by immunofluorescence staining of biopsy tissue 10. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging
System for Multiple Myeloma: A Report From International Myeloma
with anti–heavy chain antibodies. 26 Working Group. J Clin Oncol 2015;33(26):2863–9. doi:10.1200/
Management and Prognosis JCO.2015.61.2267. PubMed PMID: 26240224, PubMed Central PMCID:
PMC4846284.
The therapeutic approaches for both LCDD and HCDD are similar 11. Rajkumar SV. Smoldering multiple myeloma. UpToDate: Wolters Kluwer;
to those employed for patients with MM. Serial free light chain 2016.
26
assays can be used to monitor response to treatment in LCDD. 12. Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk
The prognoses of LCDD and HCDD vary considerably, depending smoldering myeloma. N Engl J Med 2013;369(18):1762–3. doi:10.1056/
on the nature, number, and extent of organ involvement. 26 NEJMc1310911#SA1. PubMed PMID: 24171527.
13. Rajkumar SV. Plasma cell leukemia. UpToDate: Wolters Kluwer; 2016.
14. Rajkumar SV. Diagnosis and management of solitary plasmacytoma of
ON the hOriZON bone. UpToDate: Wolters Kluwer; 2016.
15. Rajkumar SV. Diagnosis and management of solitary extramedullary
• Two monoclonal antibody drugs (mAb) have recently been approved plasmacytoma. UpToDate: Wolters Kluwer; 2016.
by the FDA for the treatment of multiple myeloma, with more on the
way. 16. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification
• Caution is warranted when monitoring myeloma patients on mAb and response assessment of multiple myeloma. Leukemia 2009;23(1):3–9.
drugs, as these biologicals may cause false positive results by protein doi:10.1038/leu.2008.291. PubMed PMID: 18971951, PubMed Central
electrophoresis of the serum and immunofixation electrophoresis (IFE). PMCID: PMC2627786.
17. Rajkumar SV. POEMS syndrome. UpToDate: Wolters Kluwer; 2016.
18. Rajkumar SV. Epidemiology, pathogenesis, clinical manifestations and
Please check your eBook at https://expertconsult.inkling.com/ diagnosis of Waldenstrom macroglobulinemia. UpToDate: Wolters
Kluwer; 2016.
for self-assessment questions. See inside cover for registration 19. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of
details. Waldenstrom’s macroglobulinemia: consensus panel recommendations
from the Second International Workshop on Waldenstrom’s
REFERENCES Macroglobulinemia. Semin Oncol 2003;30(2):110–15. doi:10.1053/
sonc.2003.50082. PubMed PMID: 12720118.
1. Rajkumar SV. Diagnosis of monoclonal gammopathy of undetermined 20. Rajkumar SV. Treatment and prognosis of Waldenstrom
significance. UpToDate: Wolters Kluwer; 2016. macroglobulinemia. UpToDate: Wolters Kluwer; 2016.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal 21. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment
gammopathy of undetermined significance. N Engl J Med recommendations for patients with Waldenstrom macroglobulinemia
2006;354(13):1362–9. doi:10.1056/NEJMoa054494. PubMed PMID: (WM) and related disorders: IWWM-7 consensus. Blood
16571879. 2014;124(9):1404–11. doi:10.1182/blood-2014-03-565135. PubMed
3. International Myeloma Working Group. Criteria for the classification of PMID: 25027391, PubMed Central PMCID: PMC4148763.
monoclonal gammopathies, multiple myeloma and related disorders: a 22. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and
report of the International Myeloma Working Group. Br J Haematol response to fludarabine therapy in patients with Waldenstrom
2003;121(5):749–57. PubMed PMID: 12780789. macroglobulinemia: results of United States intergroup trial (Southwest
4. Rajkumar SV. Clinical course and management of monoclonal Oncology Group S9003). Blood 2001;98(1):41–8. PubMed PMID:
gammopathy of undetermined significance. UpToDate: Wolters Kluwer; 11418461.
2016. 23. Rajkumar SV. The heavy chain diseases. UpToDate: Wolters Kluwer; 2016.
5. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is 24. Rajkumar SV. Clinical presentation, laboratory manifestations, and
an independent risk factor for progression in monoclonal gammopathy diagnosis of immunoglobulin light chain (AL) amyloidosis (primary
of undetermined significance. Blood 2005;106(3):812–17. doi:10.1182/ amyloidosis). UpToDate: Wolters Kluwer; 2016.
blood-2005-03-1038. PubMed PMID: 15855274, PubMed Central 25. Gertz MA. How to manage primary amyloidosis. Leukemia
PMCID: PMC1895159. 2012;26(2):191–8. doi:10.1038/leu.2011.219. PubMed PMID: 21869840.
6. Rajkumar SV. Clinical features, laboratory manifestations, and diagnosis 26. Rajkumar SV. Prognosis and treatment of immunoglobulin light chain
of multiple myeloma. UpToDate: Wolters Kluwer; 2016. (AL) amyloidosis and light and heavy chain deposition diseases.
7. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly UpToDate: Wolters Kluwer; 2016.
diagnosed multiple myeloma. Mayo Clin Proc 2003;78(1):21–33. 27. Oe Y, Soma J, Sato H, et al. Heavy chain deposition disease: an overview.
doi:10.4065/78.1.21. PubMed PMID: 12528874. Clin Exp Nephrol 2013;17(6):771–8. doi:10.1007/s10157-013-0812-x.
8. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma PubMed PMID: 23652830.
Working Group updated criteria for the diagnosis of multiple myeloma.